Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0080915 |
| Name | histiocytic sarcoma |
| Definition | A histiocytic and dendritic cell cancer that is characterized by the presence of neoplastic cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer histiocytic and dendritic cell cancer histiocytic sarcoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| MAP2K1 F53L | Trametinib | histiocytic sarcoma | predicted - sensitive | detail... |
| BRAF V600E | Trametinib | histiocytic sarcoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05961761 | Phase II | Pembrolizumab + Propranolol | Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients (PROPANE) | Recruiting | SWE | NOR | DNK | 0 |
| NCT06712810 | Phase I | Adrixetinib | Q702 for the Treatment of Patients with Hematologic Malignancies | Recruiting | USA | 0 |